These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 15282444)

  • 1. Natriuretic peptides and the management of heart failure.
    Calderone A
    Minerva Endocrinol; 2004 Sep; 29(3):113-27. PubMed ID: 15282444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The therapeutic effect of natriuretic peptides in heart failure; differential regulation of endothelial and inducible nitric oxide synthases.
    Calderone A
    Heart Fail Rev; 2003 Jan; 8(1):55-70. PubMed ID: 12652160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance.
    Abassi Z; Karram T; Ellaham S; Winaver J; Hoffman A
    Pharmacol Ther; 2004 Jun; 102(3):223-41. PubMed ID: 15246247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pregnancy alters nitric oxide synthase and natriuretic peptide systems in the rat left ventricle.
    Jankowski M; Wang D; Mukaddam-Daher S; Gutkowska J
    J Endocrinol; 2005 Jan; 184(1):209-17. PubMed ID: 15642797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardioprotective functions of atrial natriuretic peptide and B-type natriuretic peptide: a brief review.
    Woods RL
    Clin Exp Pharmacol Physiol; 2004 Nov; 31(11):791-4. PubMed ID: 15566395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recognized molecular mechanisms of heart failure: approaches to treatment.
    Ceconi C; Cargnoni A; Curello S; Ferrari R
    Rev Port Cardiol; 1998 Oct; 17 Suppl 2():II79-91. PubMed ID: 9835784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased expression of the renin-angiotensin system and mast cell density but not of angiotensin-converting enzyme II in late stages of human heart failure.
    Batlle M; Roig E; Perez-Villa F; Lario S; Cejudo-Martin P; García-Pras E; Ortiz J; Roqué M; Orús J; Rigol M; Heras M; Ramírez J; Jimenez W
    J Heart Lung Transplant; 2006 Sep; 25(9):1117-25. PubMed ID: 16962475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathophysiological significance and clinical application of ANP and BNP in patients with heart failure.
    Yoshimura M; Yasue H; Ogawa H
    Can J Physiol Pharmacol; 2001 Aug; 79(8):730-5. PubMed ID: 11558682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natriuretic peptides: biochemistry, physiology, and therapeutic role in heart failure.
    Stoupakis G; Klapholz M
    Heart Dis; 2003; 5(3):215-23. PubMed ID: 12783635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Atrial natriuretic peptide in cardiac insufficiency].
    Riegger AJ
    Arzneimittelforschung; 1988 Mar; 38(3A):479-83. PubMed ID: 2969247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased plasma levels of adrenomedullin in patients with heart failure.
    Nishikimi T; Saito Y; Kitamura K; Ishimitsu T; Eto T; Kangawa K; Matsuo H; Omae T; Matsuoka H
    J Am Coll Cardiol; 1995 Nov; 26(6):1424-31. PubMed ID: 7594065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Renin, aldosterone and prostaglandins in heart failure].
    Riegger AJ
    Z Kardiol; 1991; 80 Suppl 8():37-40. PubMed ID: 1796634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. K(ATP) activation prevents progression of cardiac hypertrophy to failure induced by pressure overload via protecting endothelial function.
    Gao S; Long CL; Wang RH; Wang H
    Cardiovasc Res; 2009 Aug; 83(3):444-56. PubMed ID: 19304734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of dystrophin breakdown and endothelial nitric-oxide synthase uncoupling accounts for cytoprotection by 3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate (DY-9760e) in left ventricular hypertrophied Mice.
    Han F; Lu YM; Hasegawa H; Kanai H; Hachimura E; Shirasaki Y; Fukunaga K
    J Pharmacol Exp Ther; 2010 Feb; 332(2):421-8. PubMed ID: 19889795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The neuroendocrinology of congestive heart failure.
    Opie LH
    Cardiovasc J S Afr; 2002; 13(4):171-8. PubMed ID: 12389058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased susceptibility to heart failure in response to volume overload in mice lacking natriuretic peptide receptor-A gene.
    Nishikimi T; Hagaman JR; Takahashi N; Kim HS; Matsuoka H; Smithies O; Maeda N
    Cardiovasc Res; 2005 Apr; 66(1):94-103. PubMed ID: 15769452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Neuroendocrine activation in heart failure I. Pathophysiology and pharmacological intervention].
    Kjaer A
    Ugeskr Laeger; 2000 Oct; 162(44):5905-9. PubMed ID: 11094549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natriuretic peptides modulate nitric oxide synthesis in cytokine-stimulated cardiac myocytes.
    Yamamoto K; Ikeda U; Shimada K
    J Mol Cell Cardiol; 1997 Sep; 29(9):2375-82. PubMed ID: 9299361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Role of nitric oxide in heart failure].
    Le Corvoisier P; Lopes ME; Su J; Hittinger L
    J Soc Biol; 2000; 194(3-4):143-9. PubMed ID: 11324316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of natriuretic peptides in cardioprotection.
    Nishikimi T; Maeda N; Matsuoka H
    Cardiovasc Res; 2006 Feb; 69(2):318-28. PubMed ID: 16289003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.